Biomarin Pharmaceutical IncChange company Symbol lookupSelect an option...BMRN Biomarin Pharmaceutical IncBLTS Bright Lights Acquisition CorpMMM 3M CoSTRR Star Equity Holdings IncBMY Bristol-Myers Squibb CoBCTX Briacell Therapeutics CorpENV Envestnet IncCDR-B Cedar Realty Trust IncEVIO EVIO IncWCC Wesco International IncGo
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
|
|
|
|
| |
Company Profile
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
Valuation Ratios
- Price/Earnings (TTM)
- 513.18x
- Price/Sales (TTM)
- 7.76x
- Price/Book (MRQ)
- 3.32x
- Price/Cash Flow (TTM)
- 102.15x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Jean-Jacques BienaimeChmn.
- Brian R. MuellerCFO
- Henry J. FuchsCorp.Exec.
- C. Greg GuyerExec.VP
- G. Eric DavisExec.VP
Address
- 105 Digital Dr
- Novato, CA 94949-8703
- Phone: (415) 506-6700
- Fax: (415) 382-7889
- https://www.biomarin.com/
Insider Trading
During the most recent quarter, 100 shares were bought, and 203K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.